Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29455925 | 0.98 | GRM5 (0.50) | GRM5PARP1KDM4ETDP1TGFBR1 | |
| SCHEMBL4186883 | 0.85 | KDM4E (0.65) | PARP1KDM4ETDP1ALDH1A1HPGD | |
| SCHEMBL646624 | 0.84 | KDM4E (0.71) | KDM4ETDP1DHODHALDH1A1LMNA | |
| SCHEMBL29693966 | 0.84 | KDM4E (0.71) | KDM4ETDP1DHODHALDH1A1LMNA | |
| SCHEMBL28687328 | 0.84 | KDM4E (0.46) | GRM5KDM4ETDP1TGFBR1TGFBR2 | |
| SCHEMBL31214633 | 0.82 | KDM4E (0.69) | KDM4ETDP1DHODHALDH1A1LMNA | |
| SCHEMBL2384672 | 0.82 | KDM4E (0.69) | KDM4ETDP1DHODHALDH1A1LMNA | |
| SCHEMBL5670751 | 0.82 | KDM4E (0.48) | GRM5KDM4ETDP1TGFBR1TGFBR2 | |
| SCHEMBL14670506 | 0.82 | KDM4E (0.48) | GRM5KDM4ETDP1ALDH1A1HPGD | |
| SCHEMBL28561077 | 0.82 | KDM4E (0.69) | KDM4ETDP1DHODHALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082310-B | Bipyridine amide derivative, and preparation and application thereof | 厦门大学 | 2024-08-20 | — | — | CN | claimed |
| CN-112892592-B | Rhodium-based electron mediator [ Cp-Rh (bpy) H 2 O] 2+ Photocatalyst Uio-66-NH fixed on 2 Method of surfacing | 中国科学院青岛生物能源与过程研究所 | 2022-11-11 | — | — | CN | claimed |
| CN-112892592-A | A rhodium-based electron mediator [ Cp Rh (bpy) H2O]2+Method for fixing photocatalyst Uio-66-NH2 surface | 中国科学院青岛生物能源与过程研究所 | 2021-06-04 | — | — | CN | claimed |
| US-5439794-A | Spectroscopically or photoactively determination when bound to Dna | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1995-08-08 | — | — | US | claimed |
| EP-0180492-B1 | MACROPOLYCYCLIC COMPLEXES OF RARE EARTH METALS AND APPLICATION AS FLUORESCENT LABELS | CIS BIO INTERNATIONAL (FR) | 1993-06-02 | — | — | EP | claimed |
| US-5157032-A | Spectroscopically or photoactively determinable | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1992-10-20 | — | — | US | claimed |
| US-5112974-A | Targets tumor cells for radiation treatment, metal complexes with amines or imines | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1992-05-12 | — | — | US | claimed |
| WO-1990005732-A1 | MIXED LIGAND COMPLEXES AND USES THEREOF AS BINDING AGENTS AND PROBRES TO DNA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFNEW YORK (US) | 1990-05-31 | — | — | WO | claimed |
| JP-57131719-A | — | — | None | — | — | JP | disclosed |
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-11-19 | — | — | US | disclosed |
| CN-116082310-B | Bipyridine amide derivative, and preparation and application thereof | 厦门大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-116082310-B | Bipyridine amide derivative, and preparation and application thereof | 厦门大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-117832605-B | Composite solid electrolyte and all-solid-state lithium battery cell | 东莞市红树林新能源有限公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-4347579-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2024-04-10 | — | — | EP | disclosed |
| JP-2007077100-A | METHOD FOR PRODUCING EPOXY COMPOUND | NAGOYA INSTITUTE OF TECHNOLOGY | 2007-03-29 | — | — | JP | disclosed |
| US-6323303-B1 | POLYMERIZING DIARYLOXY COMPOUND WITH A DIHYDRIC PHENOL COMPOUND IN THE PRESENCE OF A RUTHENIUM (II) OR RUTHENIUM (III) COMPOUND OR COMPLEX; OPTIONALLY IN PRESENCE OF A TETRAALKYL AMMONIUM OR TETRAALKYL PHOSPHONIUM SALT | GENERAL ELECTRIC COMPANY | 2001-11-27 | — | — | US | disclosed |
| WO-1998044162-A1 | DIPYRIDYLAMINE LIGAND BOUND TO A POLYMER CARRIER FOR EXTRACTING METAL IONS | BUCHMEISER MICHAEL RUDOLF (AT) | 1998-10-08 | — | — | WO | disclosed |
| US-5112974-A | Targets tumor cells for radiation treatment, metal complexes with amines or imines | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1992-05-12 | — | — | US | disclosed |
| WO-1990005732-A1 | MIXED LIGAND COMPLEXES AND USES THEREOF AS BINDING AGENTS AND PROBRES TO DNA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFNEW YORK (US) | 1990-05-31 | — | — | WO | disclosed |
| JP-S57131719-A | BLOOD SUGAR LEVEL LOWERING AGENT | CHUGAI PHARMACEUT CO LTD | 1982-08-14 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | POLQ, POLK, POLB | GRM5 4337/4885PARP1 153/4885KDM4E 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.